Dr Graeme Bilbe
Dr Bilbe has the overall responsibility for building DNDi’s project portfolio and advancing the discovery and development of new treatments for neglected diseases.
Prior to joining DNDi in 2012, Dr Bilbe was Global Head of Neuroscience Discovery at Novartis tasked with discovery and early development to proof of concept, of novel treatments for brain diseases. During his leadership of the Neuroscience group, scientific teams participated in development and registration of new therapies for Alzheimer’s disease and multiple sclerosis. Dr Bilbe also was responsible for creating and managing a portfolio of novel therapies in several disease areas encompassing projects from idea generation through Discovery up to and including clinical efficacy trials in proof of concept studies in Parkinson’s disease, Fragile X mental retardation, cognitive disorders, gastroesophageal reflux disease, epilepsy and chronic pain states. Dr Bilbe held executive leadership positions at Novartis as a member of the Novartis Institutes for Biomedical Research Leadership, Head of Research to the Neuroscience Franchise Unit, chaired the Neuroscience Disease Area Research and Development Board and was a visiting Professor at the University of Liverpool.
Dr Bilbe completed post-doctoral fellowships at the Zentrum for Molecular Biology in Heidelberg and Imperial College, London. He received his PhD in Biochemistry from the University of London, Imperial College and his BSc in Zoology and Biochemistry from the University of Nottingham. He has participated in Scientific Advisory Boards and as a scientific advisor to leadership of Biotech Companies and Public Institutions.
In 2013, Dr Bilbe was appointed member of the Tres Cantos Open Lab Foundation Governing Board and of the TDR Scientific and Technical Advisory Committee. In 2017, he was appointed Chair of the Scientific Advisory Board for the Welcome Center for Anti-Infectives Research of Dundee University.
Although Dr Bilbe grew his science during the age of molecular biology and discovered and cloned many novel genes from human and other genomes, he also brings his expertise in drug discovery and translational science and is considered by peers as an accomplished ‘drug hunter’ and developer.